Paion AG
PA8
Peringkat dalam Saham
#35735
Paion AG is a specialized pharmaceutical firm engaged in the global development... Paion AG is a specialized pharmaceutical firm engaged in the global development and commercialization of medicines for hospital settings, specifically addressing needs in sedation, anesthesia, and critical care. Its primary compound, Remimazolam, is an ultra-short-acting intravenous benzodiazepine designed as a sedative/anesthetic, currently progressing through clinical trials for applications in procedural sedation, general anesthesia, and intensive care unit sedation. The company's pipeline also includes Angiotensin II, a vasoconstrictor for treating severe low blood pressure in adults experiencing septic or other forms of distributive shock, and Eravacycline, a new fluorocycline antibiotic targeting complex intra-abdominal infections in adults. Paion AG collaborates with various partners through licensing and strategic agreements, including Cosmo Pharmaceuticals, Wuhan Humanwell Innovative Drug Research and Development Center Limited Company, Hana Pharm, Yichang Humanwell, and Mundipharma. Established in 2000, Paion AG operates from Aachen, Germany.
Harga Saham
$0.42701586
Terakhir disinkronkan: 2023-11-01
Kapitalisasi Pasar
$3.21M
Perubahan (1 hari)
16.99%
Perubahan (1 tahun)
3,295.00%
Negara
DE
Perdagangan Paion AG (PA8)
Kategori
Healthcare
Pendapatan untuk Paion AG (PA8)
Pendapatan pada Oct 2026 TTM: 0
Menurut laporan keuangan terbaru dari Paion AG, pendapatan saat ini (TTM) adalah 0. Pada tahun 2026, perusahaan menghasilkan pendapatan sebesar 0 sama dengan pendapatan pada tahun 2026 yang sebesar 0. Pendapatan adalah jumlah total yang dihasilkan dari penjualan barang atau jasa. Tidak seperti laba, tidak ada pengeluaran yang dikurangkan.
Riwayat pendapatan Paion AG dari 2004 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Mengubah |
|---|---|---|
| 2022 | $35.66M | 339.97% |
| 2021 | $8.11M | -66.14% |
| 2020 | $23.94M | 166.69% |
| 2019 | $8.98M | 182.40% |
| 2018 | $3.18M | -54.42% |
| 2017 | $6.97M | 55.50% |
| 2016 | $4.48M | 5,666.68% |
| 2015 | $77.76K | -98.14% |
| 2014 | $4.18M | -28.08% |
| 2013 | $5.81M | -83.56% |
| 2012 | $35.37M | 740.92% |
| 2011 | $4.21M | -29.69% |
| 2010 | $5.98M | 172.13% |
| 2009 | $2.20M | -50.18% |
| 2008 | $4.41M | -37.71% |
| 2007 | $7.08M | -48.53% |
| 2006 | $13.76M | -38.03% |
| 2005 | $22.21M | -3.38% |
| 2004 | $22.99M | 0.00% |
Pendapatan untuk perusahaan serupa atau pesaing
| Perusahaan | Pendapatan | Perbedaan Pendapatan | Negara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | - |
IN
|
